Flowr Corporation is undergoing a restructuring program to reduce its workforce

The Canada-based cannabis company, Flowr Corporation, announced a drastic restructuring program amid the COVID-19 crisis, which aims to reduce about 25% of the workforce in the coming weeks. The company is looking forward to reducing costs and accelerating cash flow generation, a strategy that might ensure the survival of the company during this time of economic turmoil.

Flowr Corporation announced a restructuring program aiming to reduce about 25% of its workforce. The Canada-based vertically-integrated cannabis company with operations in Canada, Europe, and Australia, has just laid off several workers in light of the global COVID-19 pandemic. This move was done through the company’s subsidiary RPK Biopharma, which owns the strategic investment company, Holigen.

Flowr has a license for the production, import and export of medical cannabis, granted by Infarmed, a government agency accountable to the Health Ministry, which evaluates, authorizes, regulates and controls human medicines as well as health products.

This reduction in the number of employees of Flowr Corporation follows a statement made by the company, which announces an overall reduction in employees of 25% in order to “thoroughly review operations to reduce costs”.

If you want to know more about Flowr Corporation’s new strategy, how the COVID-19 pandemic is affecting the cannabis sector and find out the latest cannabis news, download the Hemp.im mobile application.

Flowr Corporation strategy to ensure its survival during the COVID-19 crisis

Vinay Tolia, CEO of Flowr Corp., confirmed yesterday, March 24th, that the redundancies will also affect the Portuguese facilities in Sintra and Aljustrel. However, Tolia has not yet specified the number of workers laid off and where.

“Unfortunately, we did resort to some layoffs in our organization yesterday. The changes we announced were part of an ongoing comprehensive review of our operations to reduce costs and accelerate cash flow generation. It was an extremely difficult decision, not taken lightly, and we would like to thank the former and current employees for their tremendous contribution to the company,” he stated.

The company’s strategy to tackle the COVID-19 pandemic effects on the cannabis market, according to a statement issued yesterday, March 24th, is to ensure continuity of production at its main plant in Kelowna, Canada, focusing on the Canadian premium dried flower market for the next six months.

In Portugal, the company is still awaiting final GMP certification in Sintra and expects an outdoor harvest in Aljustrel in the fourth quarter of this year. The delay in obtaining the GMP license can, therefore, justify Flowr now focusing more on the recreational market, where it can more easily sell its production.

Flowr Corporation’s global operations

Sintra is a controlled facility for indoor cultivation, extract processing and packaging of finished products. According to Flowr, the construction of the facility is substantially completed, with 3 of the 6 total cultivation rooms currently in operation.

Obtaining GMP certification is Flowr’s top priority through its business at Holigen and is a critical step in the production and sale of medicines for distribution to any EU country. The company had its final GMP inspection in September 2019, and is still awaiting confirmation of EUDRA-GMP certification.

In Aljustrel, Holigen bet on an outdoor cultivation facility of about two hectares, which was considered a Project of National Interest by the Portuguese Government. This was, in fact, the only cannabis-related project to receive this designation. 

The company expects a gradual increase in production at the facility in Aljustrel to combine capacity with the revenue potential of an expanding European medical cannabis market. Holigen wants to plant more than 3,000 square meters this year, with a harvest planned for the fourth quarter of 2020.

__

(Featured image by Nastuh Abootalebi on Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Canna Reporter, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.